References
Goodman WG, London G, Amann K, et al. Vascular calcification in chronic kidney disease. Am J Kidney Dis 2004; 43(3): 572–9
National Kidney Foundation (NFK) K/DOQI Guidelines. K/DOQI clinical practise guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42 Suppl. 3: S1–201
Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349(5): 446–56
Coyne D, Acharya M, Qiu P, et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. Am J Kidney Dis 2006 Feb; 47(2): 263–76
Sprague SM, Llach F, Amdahl M, et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003; 63(4): 1483–90
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wetmore, J.B., Quarles, L.D. Oral Paricalcitol. Treat Endocrinol 5, 326 (2006). https://doi.org/10.2165/00024677-200605050-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00024677-200605050-00006